Opko Health, Inc.OPK

OPKO Health, the Miami-based outfit that bills itself as a fully integrated healthcare company bent on next-generation solutions, will open its second-quarter scorecard on Monday 27 July 2026 after markets close, with a follow-up call the next morning. The date is locked, the embargo is tight, and the briefing slides are already queued for the usual glossy parade of preclinical snippets and strategic waffle. What remains unspoken is how the cash machine is supposed to turn a $124.2 million revenue stream into anything resembling a profit when the same 10-Q shows an operating loss of $51.0 million for the three months to 31 March 2026. (source: OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026, https://www.opko.com/investors/news-events/press-releases/detail/548/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026)

The company markets laboratory testing services directly to physicians, geneticists, hospitals, clinics and even correctional facilities, a sprawling customer list that reads like a healthcare bingo card. Behind the scenes, the balance sheet is anchored by $1.86 billion of assets, of which $331.9 million sits in cash and equivalents, and $652.2 million in liabilities, leaving $1.20 billion of shareholders’ equity that is haemorrhaging at roughly $19 million per quarter in operating cash burn. The group’s own filings note it may receive up to $32.5 million in contingent cash if certain customer accounts deliver on revenue targets, a clause that feels less like an upside and more like a polite IOU pinned to a spreadsheet line. (source: OPK SEC EDGAR 10-Q (2026-04-28), https://www.sec.gov/Archives/edgar/data/944809/000119312526187007/opk-20260331.htm)

The operating loss of $51.0 million and net loss of $54.8 million for Q1 2026 produced a diluted loss per share of seven cents, on a diluted share count of 758.9 million. Research and development spending clocked in at $29.2 million, while inventory crept up by a rounding error of $191,000 to $64.4 million-about the price of two mid-sized diagnostic machines. The company’s conference call on Monday will no doubt field questions about how this cash-burning laboratory network is supposed to mature into the ‘next-generation’ platform, and whether the earn-out really counts as revenue before the cash lands. (source: OPK SEC EDGAR 10-Q (2026-04-28), https://www.sec.gov/Archives/edgar/data/944809/000119312526187007/opk-20260331.htm)

For a quick steer on liquidity and recent price action, the NASDAQ-listed OPK shares trade on the venue that supplies the raw volume data; the company’s own investor pages and press-releases hub are the official rails for product news such as the ENDO 2026 poster on OPKO Biologics’ OPK8801001 in acromegaly. There is no chart here, only the invitation to watch the post-earnings tape and the call transcript when they drop. (source: Press Releases hub, https://www.opko.com/investors/news-events/press-releases; Q2 2026 Financial Results Conference Call hub, https://www.opko.com/news-media/events/detail/20260727-q2-2026-financial-results-conference-call)

The biggest unanswered question is not the timing of the earnings release but the timing of the turnaround. The group’s cash runway is visible in the $331.9 million on hand, but the burn rate is visible too: if the operating cash outflow stays north of $19 million each quarter, the clock is ticking. Until the slide deck stops pointing to preclinical posters and starts pointing to booked cash, the ‘next-generation’ label reads more like next-quarter’s losses. (source: OPK SEC EDGAR 10-Q (2026-04-28), https://www.sec.gov/Archives/edgar/data/944809/000119312526187007/opk-20260331.htm)